The antiangiogenic efficacy of NGR-modified PEG–DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats

References

• Folkman J. (1996). Fighting cancer by attacking its blood supply. Sci Am, 275, 150–154.
   PubMed Web of Science ®Google Scholar
• Sato TN. (1998). A new approach to fighting cancer? Proc Natl Acad Sci USA, 95, 5843–5844.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev, 60, 1615–1626.
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377–380.
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. (2000). Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res, 60, 722–727.
   PubMed Web of Science ®Google Scholar
• Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Park HJ, Shim BS, Choi SH, Kwon HJ. (2003). Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol, 10, 695–704.
   PubMed Web of Science ®Google Scholar
• Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A. (2002). Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res, 62, 867–874.
   PubMed Web of Science ®Google Scholar
• van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, Boven E, Hoekman K, Pinedo HM. (2002). A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharmacol, 63, 897–908.
   PubMed Web of Science ®Google Scholar
• Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med, 5, 1032–1038.
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M. (2003). Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res, 63, 7400–7409.
   PubMed Web of Science ®Google Scholar
• Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ. (2007). Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs, 18, 1189–1200.
   PubMed Web of Science ®Google Scholar
• Holland EC. (2001). Progenitor cells and glioma formation. Curr Opin Neurol, 14, 683–688.
   PubMed Web of Science ®Google Scholar
• Cimini A, Cristiano L, Colafarina S, Benedetti E, Di Loreto S, Festuccia C, Amicarelli F, Canuto RA, Cerù MP. (2005). PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). Int J Cancer, 117, 923–933.
   PubMed Web of Science ®Google Scholar
• Koo YE, Reddy GR, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Ross BD, Kopelman R. (2006). Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev, 58, 1556–1577.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2001). BBB-Genomics: creating new openings for brain-drug targeting. Drug Discov Today, 6, 381–383.
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Sawaya R. (2000). Antiangiogenesis – therapeutic strategies and clinical implications for brain tumors. J Neurooncol, 50, 189–200.
   PubMed Web of Science ®Google Scholar
• Kunz J, Krause D, Kremer M, Dermietzel R. (1994). The 140-kDa protein of blood-brain barrier-associated pericytes is identical to aminopeptidase N. J Neurochem, 62, 2375–2386.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Cazenave LA, Donehower RC. (1990). Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst, 82, 1247–1259.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. (2001). Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer, 37, 1590–1598.
   PubMed Web of Science ®Google Scholar
• Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. (1996). The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res, 2, 1843–1849.
   PubMed Web of Science ®Google Scholar
• Ng SS, Figg WD, Sparreboom A. (2004). Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res, 64, 821–824.
   PubMed Web of Science ®Google Scholar
• Ong BY, Ranganath SH, Lee LY, Lu F, Lee HS, Sahinidis NV, Wang CH. (2009). Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials, 30, 3189–3196.
   PubMed Web of Science ®Google Scholar
• Ranganath SH, Wang CH. (2008). Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials, 29, 2996–3003.
   PubMed Web of Science ®Google Scholar
• Kastantin M, Ananthanarayanan B, Karmali P, Ruoslahti E, Tirrell M. (2009). Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000)micelles. Langmuir, 25, 7279–7286.
   PubMed Web of Science ®Google Scholar
• Chen XM, Wang X, Huang Y, Zhang X, Zhang Q. (2009). A comparison study of the targeting properties of NGR-liposomes and RGD-liposomes towards human umbilical vein endothelial cells. J Chin Pharm Sci, 18, 162–169.
   Google Scholar
• Zhang XC, Jackson JK, Burt HM. (1996). Development of amphiphilic diblock copolymers as micellar carriers of taxol. Inter J Pharm 132, 195–206.
   Web of Science ®Google Scholar
• Vichai V, Kirtikara K. (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc, 1, 1112–1116.
   PubMed Web of Science ®Google Scholar
• von Eckardstein KL, Patt S, Kratzel C, Kiwit JC, Reszka R. (2005). Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases. J Neurooncol, 72, 209–215.
   PubMed Web of Science ®Google Scholar
• Baskaya MK, Dogan A, Rao AM, Dempsey RJ. (2000). Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg, 92, 448–452.
   PubMed Web of Science ®Google Scholar
• Petrangolini G, Supino R, Pratesi G, Dal Bo L, Tortoreto M, Croce AC, Misiano P, Belfiore P, Farina C, Zunino F. (2006). Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther, 318, 939–946.
   PubMed Web of Science ®Google Scholar
• Liu XR, Wu KC, Huang Y, Sun JB, Ke XY, Wang JC, Lu WL, Zhang X, Zhang Q. (2008). In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions. Biol Pharm Bull, 31, 1215–1220.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2007). Drug targeting to the brain. Pharm Res, 24, 1733–1744.
   PubMed Web of Science ®Google Scholar
• Kirsch M, Schackert G, Black PM. (2000). Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol, 50, 149–163.
   PubMed Web of Science ®Google Scholar
• Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P. (2003). Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model. J Invest Dermatol, 120, 476–482.
   PubMed Web of Science ®Google Scholar
• Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. (2003). Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res, 9, 2335–2341.
   PubMed Web of Science ®Google Scholar
• Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M. (2004). Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer, 110, 117–124.
   PubMed Web of Science ®Google Scholar
• Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M. (2008). Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer, 122, 452–460.
   PubMed Web of Science ®Google Scholar
• Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U, Berghaus A, Dellian M. (2008). Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res, 14, 4603–4611.
   PubMed Web of Science ®Google Scholar
• Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, Teifel M, Alken P, Michel MS. (2009). Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep, 22, 321–326.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. (2001). Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J Control Release, 77, 27–38.
   PubMed Web of Science ®Google Scholar